Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2001-08-09
2008-07-29
Allen, Marianne P (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C530S350000
Reexamination Certificate
active
07405278
ABSTRACT:
An object of the present invention is to provide a chimera VEGF-E having a reduced antigenicity while maintaining the activity of VEGF-E. The present invention provides a chimera protein having an activity of growing vascular endothelial cells, which is obtained by substituting a part of the sequence of a VEGF analogous protein having an activity of vascularization that binds to KDR (VEGF receptor-2) but does not bind to Flt-1 (VEGF receptor-1) with a corresponding sequence of a human-derived VEGF analogous protein.
REFERENCES:
patent: 5994300 (1999-11-01), Bayne et al.
patent: 6140073 (2000-10-01), Bayne et al.
patent: 6569434 (2003-05-01), Bayne et al.
patent: 2005/0267024 (2005-12-01), Alitalo et al.
patent: 98/49300 (1998-11-01), None
Napoleone Ferrara et al., “The Biology of Vascular Endothelial Growth Factor”, Endocrine Reviews, vol. 18, No. 1, pp. 4-25 (1997).
Masabumi Shibuya, “Role of VEGF-FLT Receptor System in Normal and Tumor Angiogenesis”, Advances in Cancer Research, vol. 67, pp. 281-316 (1995).
M. Shibuya et al., “Structure and Function of Vascular Endothelial Growth Factor Receptor-1 and -2”, Current Topics in Microbiology and Immunology, vol. 237, pp. 59-83 (1999).
Tomoko Takahashi et al., “VEGF Activates Protein Kinase C-Dependent, but Ras-Independent Raf-MEK-MAP Kinase Pathway for DNA Synthesis in Primary Endothelial Cells”, Oncogene, vol. 18, pp. 2221-2230 (1999).
Bernhard Barleon et al., “Migration of Human Monocytes in Response to Vascular Endothelial Growth Factor (VEGF) is Mediated Via the VEGF Receptor flt-1”, Blood, vol. 87, No. 8, pp. 3336-3343 (1996).
Sachiyo Ogawa et al., “A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain”, The Journal of Biological Chemistry, vol. 273, No. 47, pp. 31273-31282 (1998).
David J. Lyttle et al., “Homologs of Vascular Endothelial Growth Factor are Encoded by the Poxvirus Orf Virus”, Journal of Virology, vol. 68, No. 1, pp. 84-92 (1994).
Marlene Meyer et al., “A Novel Endothelial Growth Factor Encoded by Orf Virus, VEGF-E, Mediates Angiogenesis Via Signalling Through VEGFR-2 (KDR) but not BEGFR-1 (Flt-1) Receptor Tyrosine Kinases”, The EMBO Journal, vol. 18, No. 2, pp. 363-374 (1999).
Nader Rahimi et al., “Receptor Chimeras Indicate that the Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Modulates Mitogenic Activity of VEGFR-2 in Endothelial Cells”, The Journal of Biological Chemistry, vol. 275, No. 22, pp. 16986-16992 (2000).
M. Clauss et al., “Vascular Permeability Factor: A Tumor-Derived Polypeptide that Induces Endothelial Cell and monocyte Procoagulant Activity, and Promotes Monocyte Migration”, J. Exp. Med., vol. 172, pp. 1535-1545 (1990).
Allen Marianne P
Greenblum & Bernstein P.L.C.
LandOfFree
Chimeric human-type vascular endothelial cell growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric human-type vascular endothelial cell growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric human-type vascular endothelial cell growth factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3964395